在程序性死亡受体 1 配体（PD-L1）抑制剂和化疗失败后，奥拉帕尼对 BRCA2 基因改变的尿路上皮癌有显著疗效。 - Suppr

Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.

作者信息

Necchi Andrea, Raggi Daniele, Giannatempo Patrizia, Alessi Alessandra, Serafini Gianluca, Colecchia Maurizio, Ali Siraj M, Chung Jon H

机构信息

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

出版信息

Eur J Cancer. 2018 Jun;96:128-130. doi: 10.1016/j.ejca.2018.03.021. Epub 2018 Apr 18.

DOI:10.1016/j.ejca.2018.03.021

PMID:29680362

Abstract

摘要

相似文献

Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.在程序性死亡受体 1 配体（PD-L1）抑制剂和化疗失败后，奥拉帕尼对 BRCA2 基因改变的尿路上皮癌有显著疗效。

Eur J Cancer. 2018 Jun;96:128-130. doi: 10.1016/j.ejca.2018.03.021. Epub 2018 Apr 18.

Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.尿路上皮膀胱癌中免疫检查点抑制剂早期开发的方法学考量

Eur Urol. 2017 May;71(5):840-841. doi: 10.1016/j.eururo.2016.09.044. Epub 2016 Oct 6.

Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.免疫疗法之外——晚期尿路上皮癌患者的新希望。

Acta Oncol. 2019 Jul;58(7):951-952. doi: 10.1080/0284186X.2019.1631478. Epub 2019 Jun 24.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.食品和药物管理局/EMA 批准的程序性死亡配体-1 检测在尿路上皮癌中的表现，重点是为阿替利珠单抗和帕博利珠单抗一线治疗进行的治疗分层。

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

Olaparib, a new hope for ovarian cancer.奥拉帕尼，卵巢癌的新希望。

Indian J Cancer. 2020 Jul-Sep;57(3):346-347. doi: 10.4103/ijc.IJC_1_19.

First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.一线免疫检查点抑制剂联合治疗化疗适用的转移性尿路上皮癌患者：系统评价和荟萃分析。

Eur J Cancer. 2021 Jul;151:35-48. doi: 10.1016/j.ejca.2021.03.049. Epub 2021 May 4.

Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?在免疫治疗时代，铂类化疗后维持治疗在膀胱癌中是否有作用？

Future Oncol. 2019 Dec;15(34):3877-3879. doi: 10.2217/fon-2019-0542. Epub 2019 Nov 15.

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.转移性尿路上皮癌免疫检查点抑制剂治疗反应的生物标志物。

Front Immunol. 2020 Aug 25;11:1900. doi: 10.3389/fimmu.2020.01900. eCollection 2020.

Pembrolizumab as second-line treatment for urothelial cancer.帕博利珠单抗作为尿路上皮癌的二线治疗药物。

Lancet Oncol. 2017 Apr;18(4):e197. doi: 10.1016/S1470-2045(17)30156-0. Epub 2017 Feb 24.

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.NPM1 上调 PD-L1 的转录并抑制三阴性乳腺癌中的 T 细胞活性。

Nat Commun. 2020 Apr 3;11(1):1669. doi: 10.1038/s41467-020-15364-z.

引用本文的文献

PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety.PARP抑制剂用于转移性尿路上皮癌：疗效与安全性的系统评价

Bladder Cancer. 2023 Dec 13;9(4):365-376. doi: 10.3233/BLC-230071. eCollection 2023.

Personalized treatment with PARP inhibitors in advanced urothelial carcinoma: a case report and literature review.晚期尿路上皮癌中PARP抑制剂的个体化治疗：一例病例报告及文献综述

Ther Adv Med Oncol. 2024 Apr 16;16:17588359241245283. doi: 10.1177/17588359241245283. eCollection 2024.

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).在一项 2 期、开放标签试验（ATLAS）中，鲁卡帕利在先前治疗过的、局部晚期或转移性尿路上皮癌中的疗效和安全性。

BMC Cancer. 2021 May 24;21(1):593. doi: 10.1186/s12885-021-08085-z.

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.奥拉帕利对携带BRCA2致病种系突变的复发性尿路上皮癌有效：关于奥拉帕利治疗复发性尿路上皮癌疗效的首次报告

Ther Adv Med Oncol. 2020 Nov 11;12:1758835920970845. doi: 10.1177/1758835920970845. eCollection 2020.

Pan-Cancer Analysis of and Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.全基因组杂合性缺失所测量的[具体基因]基因组改变及其与基因组不稳定性的关联的泛癌分析

JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30.

Going to extremes: determinants of extraordinary response and survival in patients with cancer.走向极端：癌症患者非凡反应和生存的决定因素。

Nat Rev Cancer. 2019 Jun;19(6):339-348. doi: 10.1038/s41568-019-0145-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献